Gary Richardson

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al. · Journal of Clinical Oncology · 2007 · 2K citations

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Stephen Chan, Kay Friedrichs, D. Noel et al. · Journal of Clinical Oncology · 1999 · 638 citations

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 374 citations

Chemotherapy Versus Chemotherapy, Oncology, Platinum-refractory Ovarian Cancer +9

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Bradley J. Monk, Andrés Poveda, Ignace Vergote et al. · The Lancet Oncology · 2014 · 304 citations

Oncology, Placebo-controlled Phase 3, Metronomic Therapy +8

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Joachim von Pawel, Reinhard von Roemeling, U. Gatzemeier et al. · Journal of Clinical Oncology · 2000 · 285 citations